August 17, 2017
SCIBAC USES HORIZONTAL GENE TRANSFER TO ENGINEER THERAPEUTIC BACTERIA
SciBac Inc. is using old-school genetics to make therapeutic bacteria that can battle pathogenic organisms and antibiotic-resistant infections. The approach uses horizontal gene transfer to move therapeutic genes from newly discovered species into strains already deemed safe for humans by FDA.
July 18, 2017
SciBac will use its DRIVE technology platform to develop non-GMO hybrid microorganisms for the purpose of creating a cost-efficient expression of enzymes for Novozymes.
May 3, 2017
Empowering the Cutting-Edge Companies of Tomorrow, Today SciBac announced as a finalist, having been judged by experts with entrepreneurial, investment, start-up, economic development, capital formation, and academic backgrounds from both the public and private sectors.
Apr 13, 2017
Jeanette Mucha, CEO of SciBac, said: “The Breakout Labs grant will allow us to further advance our C. diff program, developing a live biotherapeutic that can destroy the harmful C. diff pathogen without antibiotics, while nurturing a healthy gut microbiome.”